GPCR News

Post: Blog2_Post

Feb 28, 20221 min read

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

Updated: Aug 23, 2022

March 2022

"February 17, 2022 08:00 AM Eastern Standard Time

SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships."

Recent Posts

See All

Emerging approaches for decoding neuropeptide transmission

November 2022 "Neuropeptides produce robust effects on behavior across species, and recent research has benefited from advances in...

Location bias contributes to functionally selective responses of biased CXCR3 agonists

November 2022 "Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling...

Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...

November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...

GPCR News

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

Recent Posts

Comments